Search

MSK experts participated in the 2021 People v. Cancer summit, hosted by The Atlantic, which explored the latest in cancer research and the important ways in which prevention, diagnosis, treatment, and well-being are interrelated.

… Tuesday, November 23, 2021 The 2021 People v. Cancer summit, hosted by The Atlantic, explored the latest in cancer research and the important ways in which prevention, diagnosis, treatment, and well-being are interrelated. Even in the midst of a global pandemic, progress continues to be made toward not

New Lymphoma Service Chief Gilles Salles discusses his plans for research and collaborations at MSK.

… Wednesday, December 23, 2020 Summary Meet Lymphoma Service Chief Gilles Salles, who recently joined MSK after a long career in France. Gilles Salles recently joined Memorial Sloan Kettering as Chief of the Lymphoma Service within the Division of Hematologic Malignancies . Dr. Salles came to MSK after

Learn what to ask a cancer doctor at your first appointment, such as whether you need additional tests to clarify the diagnosis or guide your treatment.

… Monday, July 14, 2025 A cancer diagnosis is a life-changing event, one that can feel initially paralyzing: I have cancer, now what? The first step is to  make an appointment with an oncologist , a doctor who specializes in treating cancer. Medical oncologists work with a patient and their care team to

… Monday, July 14, 2025 El cáncer es un diagnóstico que cambia la vida y que puede parecer paralizante al principio: tengo cáncer, ¿ahora qué? El primer paso es  programar una cita con un oncólogo , un médico especializado en el tratamiento del cáncer. Los oncólogos médicos trabajan en colaboración con

MSK researchers are investigating a new way that people with bladder cancer can avoid bladder removal.

… Friday, December 16, 2022 Bladder removal ( radical cystectomy ) is an effective treatment option for muscle-invasive bladder cancer  but still a major operation.   MSK is taking a leading role in helping more people with bladder cancer keep their bladder without affecting survival rates.   A new approach

Tumor hypoxia on 18F-fluoromisonidazole (FMISO) positron emission tomography (PET) may serve as a reliable clinical biomarker of distant metastasis risk for patients with head and neck squamous cell carcinoma (HNSCC) after chemoradiotherapy (CRT), according to a study by MSK researchers.

… Tuesday, November 5, 2024 Tumor hypoxia on 18F-fluoromisonidazole (FMISO) positron emission tomography (PET) may serve as a reliable clinical biomarker of distant metastasis risk for patients with head and neck squamous cell carcinoma (HNSCC) after chemoradiotherapy (CRT), according to a study by MSK

Learn how a new technology could improve detection and treatment of certain aggressive lung and prostate cancers.

… Friday, February 6, 2026 A new technology developed at Memorial Sloan Kettering Cancer Center (MSK) shows promise for improving the detection and treatment of aggressive forms of  lung cancer  and  prostate cancer . The approach uses radioactive agents that bind to a molecule on cancer cells called DLL3

To mark National Cancer Prevention Month this February, MSK shared several tips to help reduce the risk of developing cancer.

… Tuesday, February 16, 2021 Summary Advice supports mission of National Cancer Prevention Month, as COVID-19 pandemic leads to an alarming drop in cancer screenings, diagnoses and treatment nationwide. To mark National Cancer Prevention Month this February, Memorial Sloan Kettering Cancer Center (MSK)

Memorial Sloan Kettering Cancer Center has appointed Gilles Salles, MD, PhD, Chief of the Lymphoma Service, Division of Hematologic Malignancies.

… Friday, November 12, 2021 Memorial Sloan Kettering Cancer Center (MSK) has appointed Gilles Salles, MD, PhD , as Chief of the Lymphoma Service, Division of Hematologic Malignancies. He succeeds Anas Younes, MD. Dr. Salles received his MD and PhD from the Université Claude Bernard Lyon and completed a

High-risk neuroblastoma cells harbor distinguishing molecular signatures, according to recent research.

… Friday, August 2, 2019 High-risk neuroblastoma cells harbor distinguishing molecular signatures, according to research that physician-scientists at Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine published recently in the journal Neoplasia. These unique characteristics distinguish neuroblastoma